Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with acute myeloid leukemia (AML), based on the 2022 WHO diagnostic guidelines.
• People aged between 18 and 60 years old.
• People who are reasonably active and able to care for themselves, with only mild or no limitations on daily activities (as measured by a standard medical scoring tool called the ECOG scale, scores 0–2).
• People whose heart is pumping adequately, as shown by a heart ultrasound result of 45% or higher.
• People whose kidneys are working well enough, based on a specific calculation or urine test showing sufficient kidney filtration capacity.
• People whose liver is functioning within acceptable limits, based on blood test results for liver enzymes and bilirubin (unless any abnormal results are caused by the leukemia itself).
• People who have read, understood, and signed a consent form agreeing to take part in the trial.

Who may not be able to join:

• People whose AML is a specific subtype called acute promyelocytic leukemia (APL).
• People whose AML has returned after treatment or has not responded to previous treatment.
• People whose leukemia is known to have spread to the brain or spinal cord.
• People known to be living with HIV, due to potential interactions between HIV medications and one of the trial drugs (confirm with trial site regarding HIV testing requirements).
• People with active hepatitis B or hepatitis C infections — though inactive carriers, or those with very low virus levels who are receiving permitted antiviral treatment, may not be automatically excluded (confirm with trial site).
• People who have taken certain medications that strongly affect how the body processes drugs (known as strong or moderate CYP3A inducers or inhibitors) within the 7 days before starting the trial treatment.
• People with significant heart disease that causes symptoms such as tiredness, breathlessness, or chest pain even with ordinary everyday activity, or with more severe heart conditions.
• People who need continuous oxygen therapy to manage a long-term breathing condition.
• People who are unable to swallow tablets or capsules, or whose body cannot properly absorb medications taken by mouth.
• People who have an active infection (bacterial, viral, or fungal) that is not under control.
• People who have previously been treated with the drug venetoclax, or who are currently taking part in another clinical trial involving an experimental drug.

Important: Always verify eligibility with the trial site directly before applying.